



**National Institute of Health - Pakistan**  
**(Field Epidemiology & Disease Surveillance Division)**

Phone: (92-051) 9255237 Fax: (92-051)9255099

National Focal Point for IHR



**No: F.1-22/Advisory/FEDSD/2022**

Islamabad, 20<sup>th</sup> May 2022

**Advisory for the Prevention and Control of Primary Ameobic Meningo-encephalitis (PAM) / Naegleriasis**

**Purpose of the Advisory:**

*Naegleria fowleri* is an amoeba, being a thermophilic unicellular organism, preferentially inhabits in warm freshwater (for example, lakes, pools, rivers, and hot springs) and soil. A rare but invariably fatal disease that was very first detected in Australia in 1965. Deaths related to PAM have been regularly reported from Karachi since 2008. With recently reported case of this year, the total count of cases has climbed up to 147 in country during last 14 years.

To mitigate the risks associated with the hot season ahead, it is imperative to undertake immediate and long term preventive measures in mega cities particularly Karachi. Vigilant surveillance is also imperative to pick the suspected cases for early disease confirmation and ensuring aggressive measures to interrupt further transmission.

The objective of this advisory is to alert the public health authorities, water and sanitation agencies and other relevant stakeholders to undertake necessary steps for prevention and control of PAM across Pakistan especially Karachi.

**Basic Information:**

*N. fowleri* (also known as brain eating amoeba) is a single-celled, thermophilic, free-living pathogen found widely in freshwater environments i.e. warm bodies of fresh water, such as lakes, rivers, hot springs and even in soil. Despite lower incidence, the PAM disease is also widely distributed in tropical areas and mostly occurs during hot summer months. Most cases of PAM arise from freshwater sources (lakes, pools) but an increasing number are now linked to drinking water systems.

The acute infection in the human body is developed when water containing *N. fowleri* is forcefully inhaled into the upper nasal passages during bathing, swimming, or other recreational activities, followed by migration of the amoebae to the brain via the olfactory nerve. Within the brain, *N. fowleri* causes extensive inflammation, hemorrhage, and necrosis, leading to death in 3 to 7 days.

**Clinical presentation:**

Incubation period ranges from 2 to 15 days with median 7 days, Clinical features of PAM are quite similar to meningitis with initial presentation of sudden onset of frontal or temporal headache, high fever, nuchal rigidity, anorexia, vomiting, irritability and restlessness. Other symptoms such as photophobia, neurological abnormalities, including altered mental status, ataxia, cranial nerve palsy, hallucinations, delirium and coma usually occur late in the clinical course leading to death in 3-8 days. The fatality rate is over 97%.

**Contd on P/2**



**Diagnosis:**

The diagnosis is based on history, clinical examination, signs and symptoms. CSF sample may be collected for microscopy and advanced referral testing. Because of the rarity of the infection and difficulty in initial detection, about 75% of case diagnoses are made after death of the patient.

**Laboratory confirmation:**

PAM infection can be confirmed through the below mentioned laboratory procedures:

Laboratory test	Findings
Direct Visualization	The motile amoeba can often be seen moving under a microscope in a fresh sample of CSF. The amoeba can also be stained with a variety of stains, such as Giemsa-Wright or a modified trichrome stain, for identification.
Antigen Detection	A specific antibody to <i>N. fowleri</i> can be used in conjunction with another antibody that deposits a chemical (immunohistochemistry [IHC]) or glows under specific types of light (indirect immunofluorescence [IIF]) to directly stain the amoebic antigens in tissue.
Polymerase Chain Reaction (PCR)	Specific molecular tools can amplify DNA from the amoeba in CSF or tissue.
Amoeba Culture	The amoeba can be grown in culture to increase the likelihood of detecting the amoeba by direct visualization or PCR
Environmental detection	Water samples can be collected, concentrated, and put into culture to grow and select for <i>N. fowleri</i>

**Medical Treatment:** Early diagnosis and treatment are crucial for survival.

- Suspected cases should immediately be reported to health authorities for corrective measures.
- Rapid diagnosis and intensive supportive care may provide the likelihood of survival. In few such documented cases, the combination of 3 drugs; **Amphotericin B** (IV/Intrathecal), Rifampicin (Oral 10 mg/ Kg/day) and **Fluconazole** (IV/ oral 10 mg/ kg/ day) is used along with **steroids**.
- Azithromycin has both in vitro and in vivo efficacy against *N. fowleri* and may be tried as an adjunct to Amphotericin B. Miltefosine has also shown some in vitro amoeba- killing activity against free-living amoebae, including *N. fowleri*.

**Prevention and Control measures:**

- *N. fowleri* cannot survive in clean, cool and chlorinated water. Chlorine kills *N. fowleri* and is the most effective way to disinfect swimming pools and reticulated water supplies. Maintain the chlorine level in the water, as almost all the PAM cases are linked with the use of inadequately chlorinated water.
- Community education and awareness raising assumes significance in known endemic areas. Key recommended messages may include:
  - During recreational activities like swimming, avoid diving and getting water up in the nose. Try to avoid water-related activities when the water is not chlorinated.
  - Empty and clean small collapsible bathing pools daily.
  - Ensure swimming pools and spas are adequately chlorinated and well maintained.
  - If using un-chlorinated water, don't allow water to go up in nose when bathing, showering or washing the face.
- Potentially contaminated water should not be used for any form of nasal irrigation or nasal lavage.

**Contd on P/3**



**Advise for water utilities:**

- Water supplies at risk include; reticulated raw and drinking water, lakes, dams, bores, tanks, reservoirs, pipelines, and swimming pools that are poorly maintained, under or un-chlorinated.
- Proper design, management and cleaning of assets (e.g. pipes and storage tanks) is required to minimize the sediment (which may harbour *Naegleria* cysts) and reduce water stagnation (which may lead to loss of disinfectant residual).

**Chlorination:**

- Water supplies at risk of *N. fowleri* must ensure adequate primary disinfection and maintain a chlorine residual of at least 0.5 mg/L at all times, in all parts of the distribution system. According to the World Health Organization (WHO), free chlorine having residual concentration equal or more than 0.5 mg/L, at pH less than 8.0 and at 20°C, after a contact time of at least 30 minutes is effective for chlorine disinfection.
- Regularly monitor the water temperature and chlorine residual throughout the distribution system. Periodic testing for *N. fowleri* can be carried out for risk systems.

**Risk Communications:**

Symptoms of *N. fowleri* infection are clinically similar to viral and bacterial meningitis and these conditions are much more common than amoebic meningoencephalitis. Making doctors aware about the disease may therefore, improve case detection and provide insight into human or environmental determinants of infection and allow improved assessment of treatment effectiveness.

**Health Education:**

Awareness and education in the affected areas must also be undertaken to educate people on requisite preventive measures. Households should also be warned of the potential risk, if adequate disinfection cannot be maintained throughout the distribution system.

**Disease Surveillance and Notification:**

Surveillance and notification of PAM infection should be enhanced with the dissemination of standard case definitions and diagnostics options to areas of transmission and areas at risk.

The situation may please be continuously monitored and updates along with the actions taken be kindly communicated to the NIH regularly on phone no. +92-51-9255237, Fax: +92-51-9255099, E-mail: [fedsd@nih.org.pk](mailto:fedsd@nih.org.pk)

The above 'Advisory' may please be circulated widely to all concerned.

  
Major General  
Prof. Dr. Aamer Ikram, HI(M)  
Executive Director, NIH

**Distribution Overleaf**



**Distribution:**

1. Secretary, Health Department, Government of the Punjab, Lahore
2. Secretary, Health Department, Government of Sindh, Karachi
3. Secretary, Health Department, Government of KPK, Peshawar
4. Secretary, Health Department, Government of Balochistan, Quetta
5. Secretary, Health Department, Government of AJK, Muzaffarabad
6. Secretary, Health Department, Government of Gilgit-Baltistan, Gilgit
7. Chief Executive Officer, Islamabad Healthcare Regulatory Authority, Islamabad
8. Chief Executive Officer, Punjab Healthcare Commission, Lahore
9. Chief Executive Officer, Sindh Healthcare Commission, Karachi
10. Chief Executive Officer, KPK Healthcare Commission, Peshawar
11. Director General Health Services, Government of the Punjab, Lahore
12. Director General Health Services, Government of Sindh, Hyderabad
13. Director General Health Services, Government of KPK, Peshawar
14. Director General Health Services, Government of Balochistan, Quetta
15. Director General Health Services, Government of Gilgit-Baltistan, Gilgit
16. Director General Health Services, Government of AJK, Muzaffarabad
17. Director General, National Health Emergency Preparedness and Response Network (NHEPRN), Islamabad
18. Animal Husbandry Commissioner, Mo National Food Security & Research, Islamabad
19. Executive Director, Pakistan Institute of Medical Sciences, Islamabad
20. Executive Director, Federal Government Polyclinic Hospital, Islamabad
21. Executive Director, CDA Capital Hospital, Islamabad
22. Executive Director, Federal Government TB Hospital, Rawalpindi
23. Executive Director, National Institute of Rehabilitation Medicine (NIRM), Islamabad
24. Director General Health Services, Capital Development Authority, Islamabad
25. Director General, PAEC Hospital, Islamabad
26. Director General, KRL Hospital, Islamabad
27. Director General, NESCOM Hospital, Islamabad
28. District Health Officer, ICT, Islamabad
29. Director, Central Health Establishment (CHE), Islamabad
30. Director, Nuclear Oncology & Radiotherapy Institute (NORI), Islamabad
31. Commandant, PAF Hospital, Islamabad
32. Commandant, Naval Complex Hospital, (PNS Hafeez), Islamabad
33. Medical Superintendent, Social Security Hospital, Islamabad
34. Director, Federal General Hospital, Park Road, Islamabad
35. Executive Director, Shifa International Hospital, Islamabad
36. Executive Director, Qauid-e-Azam International Hospital, Islamabad
37. Executive Director, Maroof International Hospital, Islamabad
38. Commandant, Combined Military Hospital (CMH), Rawalpindi
39. Commandant, Military Hospital (MH), Rawalpindi
40. Medical Superintendent, Cantonment General Hospital, Rawalpindi
41. Medical Superintendent, District Headquarter Hospital, Rawalpindi
42. Medical Superintendent, Fauji Foundation Hospital, Rawalpindi
43. Medical Superintendent, Holy Family Teaching Hospital, Rawalpindi
44. Medical Superintendent, Benazir Bhutto Hospital, Rawalpindi
45. Medical Superintendent, WAPDA Hospital, Rawalpindi
46. Medical Superintendent, Railway Hospital, Rawalpindi
47. In-charge, Federal Disease Surveillance Unit (FDSRU), NIH Islamabad
48. Officer In-charge, Provincial Disease Surveillance Unit (PDSRU) at Provincial Health Directorates, Lahore, Hyderabad, Peshawar, Quetta, Gilgit and Muzaffarabad
49. Deputy Commissioners with the request to direct all concerned departments at district level

**Copies to:**

1. Chief Secretary, Govt of Punjab, Sindh, KPK, Balochistan, GB and AJK.
2. Surgeon General Pakistan Army, GHQ Rawalpindi
3. Chief Commissioner, ICT Administration Islamabad
4. WHO Country Representative, Islamabad
5. SPS to Federal Minister of Health, M/o NHR&C, Islamabad
6. SPS to Secretary, M/o NHR&C, Islamabad
7. PS to Director General Health, M/o NHR&C, Islamabad